Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Wit… (NCT06200168) | Clinical Trial Compass
RecruitingPhase 3
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
China370 participantsStarted 2024-01-16
Plain-language summary
This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 years or older and aged 75 years or younger, of any nationality;
✓. Eastern Cooperative Oncology Group performance status of 0-2;
✓. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin;
✓. Predicted life expectancy of ≥3 months;
✓. Adequate bone marrow, kidney, and liver function;
✓. Adequate contraception if premenopausal women;
✓. Written informed consent by the patient before enrolment.
Exclusion criteria
✕. Patients already submitted to chemotherapy;
✕. Is scheduled to receive any non-HEC on Day 1;
✕. Is scheduled to receive any chemotherapy on days 2-4 after HEC;
✕. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;
✕
What they're measuring
1
Proportion of patients with no nausea during the overall stage